



HIKAL®

Q3 Results – FY 2013-14

Turnover up by 42% to Rs. 216 crores

Hikal declares 20% Interim Dividend

Mumbai, February 6th 2014: Hikal Ltd, the preferred long-term partner for leading global life sciences companies, announced its financial results for the third quarter ended 31st December, 2013.

The Board of the Company has declared an Interim Dividend of Rs. 2 per equity share (20%)

Performance highlights for the Quarter ended 31st December 2013

- **Net sales up by 42% to Rs.216 crores** as compared to Rs.153 crores in the corresponding quarter of the previous year.
- **Pharmaceutical sales up by 27% to Rs.113 crores** as compared to Rs.89 crores in the corresponding quarter of the previous year.
- **Crop protection sales up by 61% to Rs.103 crores** as compared to Rs.64 crores in the corresponding quarter of the previous year.
- **EBIDTA up by 14% to Rs.50 crores** as compared to Rs.44 crores in the corresponding quarter of the previous year.
- **Net Profit was up by 14% at Rs.10 crores** as compared to Rs.9 crores in the corresponding quarter of the previous year after providing **Rs. 6 crores for forward swap transactions which are notional in nature.**

Performance highlights for the 9 months ended 31st December, 2013

- **Net sales up by 28% to Rs.602 crores** as compared to Rs.471 crores in the corresponding period of the previous year.
- **Pharmaceutical sales up by 39% to Rs.367 crores** as compared to Rs.265 crores in the corresponding period of the previous year.
- **Crop protection sales up by 14 % to Rs.235 crores** as compared to Rs.206crores in the corresponding period of the previous year.
- **EBIDTA up by 6% to Rs.141 crores** as compared to Rs.133 crores in the corresponding period of the previous year.
- **Net Profit was up by 278% at Rs.61 crores** as compared to Rs.16 crores in the corresponding half year of the previous year after providing **Rs. 6 crores for forward swap transactions which are notional in nature.**



HIKAL LTD

Admn. Office : Great Eastern Chambers, CBD Belapur, Navi Mumbai - 400 614. Tel. : (91-22) 3097 3100 Fax : (91-22) 3097 3281 E-mail : info@hikal.com

Factory : T-21, MIDC Ind. Area, Taloja, Pin - 410 208, Dist. Raigad, Maharashtra. Tel. : (91-22) 3099 0100 Fax : (91-22) 2741 1844

Regd. Office : 717/718, Maker Chambers V, 7th Floor, Nariman Point, Mumbai - 400 021. Tel. : (91-22) 6630 1801 / 2283 4587 Fax : (91-22) 2283 3913

Commenting on the results, Jai Hiremath, Chairman & Managing Director, Hikal Ltd. said, “We are pleased to announce that the Board has declared an Interim Dividend of 20%. Our growth momentum continues in the third quarter of this financial year. Our revenues and EBIDTA have grown as compared to the corresponding quarter of the previous year. Our Crop Protection business has grown significantly by 61% this quarter due to the increased demand from our existing customers as well as sales from our new products added in the past year. The forecast is extremely positive from our customers for the remaining part of this financial year and the next year. Our Pharmaceutical business has also grown by 27% this quarter due to ramp up in sales of new products that were launched last year. We expect positive results in the quarters to come.”

About Hikal:

Hikal is a reliable long-term partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers. Hikal’s advanced manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal’s R&D facilities are located at Pune and Bangalore. The Pharmaceutical manufacturing facilities are situated in Jigani (Bangalore) and Panoli (Gujarat), respectively.

Safe harbor Statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Hikal Ltd. – **Debabrata Chatterjee** @+912230973100, Email – d_chatterjee@hikal.com
Strategic Growth Advisors Pvt. Ltd.- **Payal Dave**@+912261146679 – dpayal@sgapl.net

